Clinical Trial Update: Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus [Phase 1]

View source ↗

Summary

A Phase I clinical study evaluating RGB-5088 for safety and efficacy in Type 1 diabetes mellitus is currently recruiting. The trial is sponsored by Hangzhou Rep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus

Drugs mentioned

• RGB-5088

Snippet

Sponsor: Hangzhou Reprogenix Bioscience, Inc | Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus | Phase 1 | Status: RECRUITING